Dr Mark Pinese
Dr Pinese completed his undergraduate studies at UNSW Australia on the biology of ageing, before moving to the Garvan Institute to pursue cancer research.
At the Garvan Institute, Dr Pinese was a member of the world's largest sequencing effort in pancreatic cancer, and for his work received a PhD on the molecular determinants of survival of patients with pancreatic adenocarcinoma. Dr Pinese then joined the Kinghorn Centre for Clinical Genomics, where he performed rapid-turnaround genomic analysis for cancer patients, and helped to develop Australia's first clinically-accredited whole genome sequencing test for rare disease.
Dr Pinese is currently a Senior Research Officer in Garvan's Genomic Cancer Medicine Lab, where he is the lead analyst for the Medical Genome Reference Bank, and conducts research into the genetic basis of cancer risk.
In the NewsGarvan team a top performer in international genomics challenge - Jul 06, 2016
Awards and Honours
2006 - BSc (Hons) (Molecular Biology), UNSW Australia - Australia
Humphris et al (2016) Hypermutation in pancreatic cancer. Gastroenterology (in press).
Bailey et al (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531:47-52
Miller*, Morton*, Pinese*, Saturno*, et al (2016) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine 7:1063-1076
Tactacan et al (2016) The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling. Molecular Cancer 14:139
Waddell et al (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518(7540):495-501.
Biankin et al (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491(7424):399-405.
Cowley et al (2011) PINA v2.0: mining interactome modules. Nucleic Acids Research 40(D1):D862-865.
Hochgräfe et al (2010) Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Research 70(22):9391-9410.
Zardawi et al (2010) High Notch1 protein expression is an early event in breast cancer development and is associated with the HER‐2 molecular subtype. Histopathology 56(3):286-296.
Biankin et al (2009) Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 137(2):558-568.
Pinese et al (2009) Messina: A Novel Analysis Tool to Identify Biologically Relevant Molecules in Disease. PLoS ONE 4(4):e5337